STEMI
Conditions
Keywords
STEMI, Metabolomics, Biomarkers, Type 2 Diabetes Mellitus
Brief summary
This study is a retrospective case-control study. In this study, through untargeted metabolomics, investigators identified several specific changed serum metabolites in T2DM patients with or without AMI and their functions/category. Moreover, researchers selected several endogenous candidate biomarkers with larger fold change for validation in expanded population to find biomarkers which effectively predict the development of STEMI in patients with T2DM.
Interventions
DEVICEliquid chromatography-mass spectrometry (LC/MS) analysis
To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
Sponsors
Beijing Friendship Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* STEMI patients meet the diagnostic criteria of Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2015). * STMEI patients undergoing emergency PCI should undergo emergency PCI within 12 hours of onset at Beijing Friendship Hospital affiliated to Capital Medical University. * All diabetic patients meet the diagnostic criteria for type 2 diabetes. * They agreed to be enrolled in the trial and signed the informed consent.
Exclusion criteria
* Combined with severe valvular disease or congenital heart disease, hypertension, chronic kidney disease, stroke, hyperlipidemia, previous history of coronary artery disease. * Involved in acute infection, severe hepatic dysfunction, tumor, rheumatic immune disease. * Incomplete clinical information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| There are differences in the metabolic profile of diabetic patients with or without combined acute myocardial infarction | December 16th, 2020 | About 10ml of venous blood was collected on the admission, serum was separated. To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. |
Countries
China
Outcome results
None listed